|
Volumn 19, Issue 56, 2000, Pages 6670-6672
|
ONYX-015 selectivity and the p14ARF pathway
|
Author keywords
Adenovirus; ONYX 015; p14ARF; p53
|
Indexed keywords
ANTINEOPLASTIC AGENT;
GENE PRODUCT;
ONCOLYTIC VIRUS;
ONYX 015;
PROTEIN MDM2;
PROTEIN P14ARF;
PROTEIN P53;
UNCLASSIFIED DRUG;
ADENOVIRUS;
CANCER GENETICS;
CLINICAL TRIAL;
DRUG POTENCY;
DRUG SELECTIVITY;
GENE THERAPY;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
META ANALYSIS;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
VIRUS MUTANT;
VIRUS NEUTRALIZATION;
ADENOVIRUSES, HUMAN;
DRUG DELIVERY SYSTEMS;
FORECASTING;
MODELS, BIOLOGICAL;
NEOPLASMS;
PROTEINS;
SIGNAL TRANSDUCTION;
TUMOR SUPPRESSOR PROTEIN P14ARF;
TUMOR SUPPRESSOR PROTEIN P53;
VIRUS REPLICATION;
ADENOVIRIDAE;
DNA VIRUSES;
ONYX;
|
EID: 0034722895
PISSN: 09509232
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.onc.1204096 Document Type: Review |
Times cited : (40)
|
References (19)
|